Cdc Adopts New Hiv Prevention Strategies For A Changing Epidemic {#sec1}
================================================================

18 April (Reuters Health \[Megan Rauscher\])---Federal health officials with the Centers for Disease Control and Prevention (CDC) announced an initiative designed to refocus their HIV prevention efforts.

"An estimated 200,000 people in the United States do not know they are infected with HIV and tragically are not getting appropriate treatment. This is an intolerable situation," CDC director Dr. Julie Gerberding told reporters. "Our prevention efforts have stalled---we are not making the kinds of ongoing progress that you would expect given the recent advances in HIV testing," she said.

The new initiative takes advantage of the FDA-licensed rapid HIV test that can be performed in settings such as STD clinics, shelters, drug treatment centers, and correctional facilities. The fact that results are available in roughly 20 minutes, Dr. Gerberding said, means patients don\'t have to come in for a follow-up visit to get the test result.

She announced that CDC guidelines would no longer include a requirement for extensive counseling as a prerequisite to getting the HIV test. "Behavioral counseling is still critically important," Dr. Gerberding said, "but in the medical environment, this has been a barrier to getting the test done because many clinicians don\'t know how to do that kind of counseling or simply do not have the time, so we are removing that requirement as a condition for testing."

As part of the initiative, CDC will work with clinicians to make HIV testing a routine component of medical care. This means getting physicians to ask "simple questions about injection drug use and unsafe sex and offer the HIV test," Dr. Gerberding said.

Maternal HIV testing is also a big component of the initiative. "We believe very strongly that a case of perinatal transmission really represents a failure of our public health system, and we want all mothers tested for HIV infection," Dr. Gerberding said.

The CDC is recommending the opt-out approach, in which all pregnant women who have not been tested for HIV are offered the test. The goal is to make HIV testing a "routine part of perinatal care," Dr. Gerberding said, adding, "we are going to do everything we can to ensure that children born to infected mothers have access to antiretroviral therapy."

Dr. Gerberding emphasized that CDC is not recommending mandatory HIV testing of any group of people, under any circumstances. "We are simply treating an HIV test like any other test that would be a normal part of routine care," she said.

As part of the initiative, CDC will also put more focus on the HIV-infected population. In the past, most of the prevention efforts have gone toward addressing behaviors of uninfected people that put them at risk for exposure. "That needs to continue," Dr. Gerberding said, "but we haven\'t put as much emphasis on HIVinfected people as a component of our prevention paradigm as perhaps we should," she said. It\'s "very important" to make sure partners of HIV-infected patients have access to testing.

Source: Morb Mortal Wkly Rep MMWR 2003; 52:330--2.

Fda Clears Hiv Test That Gives Results In 3 Minutes {#sec2}
===================================================

17 April (Reuters Health \[Ori Twersky\])--- Canada\'s MedMira, Inc., said that it has received clearance from the US Food and Drug Administration (FDA) to market its 3-minute Reveal Rapid HIV-1 Antibody test.

Rival firm OraSure Technologies, Inc., of Bethlehem, Pennsylvania, recently won clearance for a 20-minute rapid HIV antibody test. But according to MedMira, the Reveal test has now become the fastest antibody test for HIV-1 to be cleared by the FDA.

The test has been shown to be equivalent to or better than conventional HIV diagnostic tests that typically take days to conduct, the firm added.

Dynport Smallpox Vaccine Shows Fewer Side Effects Than Dryvax in Phase I Study {#sec3}
==============================================================================

17 April (Reuters Health)---DynPort Vaccine Company, a joint venture between Computer Sciences Corporation and Porton International, said that its investigational cell-cultured smallpox vaccine (CCSV) induced fewer side effects than the historic Dryvax vaccine in a phase I trial of 350 volunteers.

All volunteers exhibited a positive response to either CCSV or Dryvax, a calflymph produced smallpox vaccine, in the recently completed trial.

DynPort said the incidence of vaccinerelated fatigue, application-site rash, increased temperature, headache, lymphangitis, and nausea was at least 8% less common among the volunteers who received CCSV rather than Dryvax.

Fda Urges Sars Precautions For Blood Banks {#sec4}
==========================================

18 April (Reuters \[Lisa Richwine\])---US officials urged precautions to keep the blood supply free from the severe acute respiratory syndrome (SARS) respiratory illness, although they said they do not know whether the virus that causes it can be transmitted through blood.

The US Food and Drug Administration (FDA) advised blood banks to ask potential donors questions aimed at identifying people who could be infected with the virus that causes SARS but are not experiencing symptoms.

People already sick from SARS would normally be turned away at blood banks anyway, since no one who is not in good health is permitted to donate blood, the FDA said.

The new questions focus on finding people who may face an elevated risk of SARS because they recently visited known high-risk areas or were exposed to someone with the illness.

People who have visited areas with high numbers of SARS cases but have no symptoms should be banned from giving blood for 14 days after their return to the United States, the FDA said. The list of such areas currently includes China, Singapore, and Hanoi.

Those who have had an acute case of SARS, based on symptoms and travel history, should be excluded from donating blood for 28 days after their symptoms have cleared up and any treatment has been completed, the FDA guidelines said.

Among the FDA\'s other suggestions is that blood banks encourage people who give blood to contact the collection agency if they develop SARS within 14 days postdonation. Blood from potentially exposed or infected people will be quarantined, the FDA said.

The FDA recommended the new bloodcollection guidelines be put in place within 30 days as a precaution while scientists work to learn more about the SARS virus. No known cases of SARS transmission via blood products have occurred, the FDA said.

"However, detection of the genes of the possible causative virus in blood has been reported in a patient with SARS. Also, as in some other viral infections, persons with SARS could potentially have virus in their blood early in infection without any symptoms," an FDA statement said.

"Therefore, transfusion transmission of SARS may be possible," the FDA said.

The agency estimated that, at most, 0.4% of potential donors will be deferred under the new guidelines.

***Editor\'s comment.*** These recommendations assume that, if the coronavirus that causes SARS is found in blood, it would be present in the blood for no more than 14 days after exposure, without development of disease, and that it would be in the blood no longer than 28 days after clearing of symptoms. Both of these assumptions are reasonable on the basis of present information. However, on the basis of evolving observations (e.g., presence of virus in stool, urine, and nasopharynx as long as 21 days after the onset of symptoms \[Peiris J. S. M., Chu C. M., Cheng V. C. C., et al. Prospective study of the clinical progression and viral load of SARS associated with coronavirus pneumonia in a community outbreak. Summary available at: http://www.who. int/csr/sars/prospectivestudy/en/index. html\]), the recommendations may need to be modified.

Us Company Tests Antidote For Anthrax {#sec5}
=====================================

1 May (Reuters Health)---A San Diego based company said it had engineered a human antibody that neutralizes anthrax toxin in rats and could potentially protect people exposed to the sometimes deadly bacteria.

"The potency this antibody exhibits is extremely high," Dr. Phillip Morrow, a researcher at Avanir Pharmaceuticals, said in a statement. "We are very encouraged by this data, and plan to develop this antibody for use as a prophylactic and therapeutic drug to prevent and treat anthrax infections."

Avanir said its antibody, called VP-8C1, acted against the molecule that anthrax toxins use to get into cells. The company presented its findings at a vaccine meeting in Maryland and said it planned to test the antibody on guinea pigs next.

Editor\'s comment. The availability of an effective antitoxin would be welcome. It might be effective for advanced clinical cases that have a poor response to antibiotic therapy. Furthermore, it might be effective against bioterrorism-associated strains that have been engineered to be resistant to multiple antibiotics.
